Q1 2026 · 13F-HR
Davern Capital Partners, LPholdings as filed
Filed 2026-05-14 · accession 0000905148-26-002267
$364.5M
Reported value
17
Positions
2026-03-31
Period end
The Brief · Davern Capital Partners, LP · Q1 2026
AI · grounded in 13F
Davern Capital Partners, LP established a new position in INSM valued at $29.85M. The fund also initiated new stakes in GENB for $7.4M and PRCT for $6.53M, while increasing its holdings in LLY by 228.39%. On the sell side, the fund closed its position in CGON, resulting in a $6.73M reduction.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 717081103 | PFE | PFIZER INC | $44.8M | 12.3% | 1,593,942 | Common | NONE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $34.6M | 9.50% | 44,800 | Common | NONE |
| 457669307 | INSM | INSMED INC | $29.9M | 8.19% | 182,562 | Common | NONE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $29.1M | 7.97% | 386,903 | Common | NONE |
| 632307104 | NTRA | NATERA INC | $28.8M | 7.90% | 143,966 | Common | NONE |
| 09075V102 | BNTX | BIONTECH SE | $27.1M | 7.44% | 305,055 | Common | NONE |
| 04016X101 | ARGX | ARGENX SE | $25.6M | 7.02% | 35,045 | Common | NONE |
| 532457108 | LLY | ELI LILLY & CO | $25.1M | 6.88% | 27,279 | Common | NONE |
| G7709Q104 | RPRX | ROYALTY PHARMA PLC | $24.9M | 6.84% | 520,009 | Common | NONE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $24.2M | 6.64% | 873,398 | Common | NONE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $23.8M | 6.52% | 1,314,748 | Common | NONE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $12.1M | 3.32% | 447,153 | Common | NONE |
| 00370M103 | ABVX | ABIVAX SA | $8.7M | 2.39% | 78,125 | Common | NONE |
| 370920100 | GENB | GENERATE BIOMEDICINES INC | $7.4M | 2.03% | 591,800 | Common | NONE |
| 74276L105 | PRCT | PROCEPT BIOROBOTICS CORP | $6.5M | 1.79% | 261,200 | Common | NONE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $6.1M | 1.67% | 126,461 | Common | NONE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $5.9M | 1.62% | 302,457 | Common | NONE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.